Resultats globals: 225 registres trobats en 0.02 segons.
Articles, 117 registres trobats
Documents de recerca, 108 registres trobats
Articles 117 registres trobats  1 - 10següentfinal  anar al registre:
1.
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels / Hong, S. (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA). University of Lübeck) ; Dobricic, Valerija (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA). University of Lübeck) ; Ohlei, O. (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA). University of Lübeck) ; Bos, I. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Vrije Universiteit Amsterdam) ; Vos, S.J.B. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Vrije Universiteit Amsterdam) ; Prokopenko, D. (Genetics and Aging Unit and McCance Center for Brain Health. Department of Neurology. Massachusetts General Hospital) ; Tijms, B.M. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Vrije Universiteit Amsterdam) ; Andreasson, U. (Clinical Neurochemistry Laboratory. Sahlgrenska University Hospital) ; Blennow, K. (Clinical Neurochemistry Laboratory. Sahlgrenska University Hospital) ; Vandenberghe, R. (Neurology Service. University Hospital Leuven) ; Gabel, Silvy (Laboratory for Cognitive Neurology. Department of Neurosciences. KU Leuven) ; Scheltens, P. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Vrije Universiteit Amsterdam) ; Teunissen, C.E. (Neurochemistry Laboratory. Department of Clinical Chemistry. Amsterdam Neuroscience. Amsterdam University Medical Centers. Vrije Universiteit) ; Engelborghs, S. (Department of Neurology and Center for Neurosciences. UZ Brussel and Vrije Universiteit Brussel (VUB)) ; Frisoni, G. (IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli) ; Blin, O. (AIX Marseille University. INS. Ap-hm) ; Richardson, J.C. (Neurosciences Therapeutic Area. GlaxoSmithKline R&D) ; Bordet, R. (Inserm. CHU Lille. University of Lille) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Popp, J. (Old Age Psychiatry. Department of Psychiatry. University Hospital of Lausanne) ; Clark, C. (Centre for Gerontopsychiatric Medicine. Department of Geriatric Psychiatry. University Hospital of Psychiatry Zurich) ; Peyratout, G. (Old Age Psychiatry. Department of Psychiatry. University Hospital of Lausanne) ; Martinez-Lage, P. (Department of Neurology. Center for Research and Advanced Therapies. CITA-Alzheimer Foundation) ; Tainta, M. (Department of Neurology. Center for Research and Advanced Therapies. CITA-Alzheimer Foundation) ; Dobson, R.J.B. (The National Institute for Health Research University College London Hospitals Biomedical Research Centre. University College London) ; Legido-Quigley, C. (Steno Diabetes Center. Copenhagen. Denmark and Institute of Pharmaceutical Sciences. King's College London) ; Sleegers, K. (Department of Biomedical Sciences. University of Antwerp) ; Van Broeckhoven, C. (Department of Biomedical Sciences. University of Antwerp) ; Tanzi, R.E. (Genetics and Aging Unit and McCance Center for Brain Health. Department of Neurology. Massachusetts General Hospital) ; ten Kate, M. (Department of Radiology and Nuclear Medicine. Amsterdam University Medical Centers. Amsterdam Neuroscience) ; Wittig, M. (Institute of Clinical Molecular Biology. Christian-Albrechts-University of Kiel) ; Franke, A. (Institute of Clinical Molecular Biology. Christian-Albrechts-University of Kiel) ; Lill, C.M. (Ageing Epidemiology Research Unit. School of Public Health. Imperial College) ; Barkhof, F. (Institutes of Neurology and Healthcare Engineering. University College London) ; Lovestone, Simon (Department of Psychiatry. University of Oxford) ; Streffer, J. (Translational Medicine Neuroscience. UCB Biopharma SPRL. Braine l'Alleud) ; Zetterberg, H. (UCL Institute of Neurology (Regne Unit). UK Dementia Research Institute) ; Visser, P.J. (Department of Neurobiology. Care Sciences and Society. Division of Neurogeriatrics. Karolinska Instutet) ; Bertram, L. (Department of Psychology. University of Oslo)
Introduction: Neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), and neurogranin (Ng) are biomarkers for Alzheimer's disease (AD) to monitor axonal damage, astroglial activation, and synaptic degeneration, respectively. [...]
2021 - 10.1002/alz.12330
Alzheimer's & Dementia, Vol. 17 Núm. 10 (october 2021) , p. 1628-1640  
2.
16 p, 1.7 MB Sleep disorders in adults with down syndrome / Giménez, Sandra (Institut d'Investigació Biomèdica Sant Pau) ; Altuna-Azkargorta, Miren (Institut d'Investigació Biomèdica Sant Pau) ; Blessing, E. (Department of Psychiatry. NYU Langone Health) ; Osorio, R.M. (Department of Psychiatry. NYU Langone Health) ; Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Sleep disorders, despite being very frequent in adults with Down syndrome (DS), are often overlooked due to a lack of awareness by families and physicians and the absence of specific clinical sleep guidelines. [...]
2021 - 10.3390/jcm10143012
Journal of clinical medicine, Vol. 10 Núm. 14 (february 2021) , p. 3012  
3.
11 p, 1.6 MB Association of Apolipoprotein e ϵ4 Allele with Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults with down Syndrome / Bejanin, Alexandre (Institut d'Investigació Biomèdica Sant Pau) ; Iulita, M. Florencia (Institut d'Investigació Biomèdica Sant Pau) ; Vilaplana, Eduard (Institut d'Investigació Biomèdica Sant Pau) ; Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau) ; Benejam, B. (Barcelona Down Medical Center. Fundació Catalana Síndrome de Down) ; Videla Toro, Laura (Institut d'Investigació Biomèdica Sant Pau) ; Barroeta, Isabel (Institut d'Investigació Biomèdica Sant Pau) ; Fernandez, S. (Universitat Autònoma de Barcelona) ; Altuna-Azkargorta, Miren (Institut d'Investigació Biomèdica Sant Pau) ; Pegueroles, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Montal, Victor (Institut d'Investigació Biomèdica Sant Pau) ; Valldeneu, Silvia (Institut d'Investigació Biomèdica Sant Pau) ; Giménez, Sandra (Institut d'Investigació Biomèdica Sant Pau) ; González-Ortiz, S. (Hospital del Mar (Barcelona, Catalunya)) ; Muñoz, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Padilla, Concepción (Institut d'Investigació Biomèdica Sant Pau) ; Aranha, Mateus (Institut d'Investigació Biomèdica Sant Pau) ; Estellés, T. (Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED)) ; Illán-Gala, Ignacio (Institut d'Investigació Biomèdica Sant Pau) ; Belbin, Olivia (Institut d'Investigació Biomèdica Sant Pau) ; Camacho, Valle (Institut d'Investigació Biomèdica Sant Pau) ; Wilson, L.R. (Cambridge Intellectual and Developmental Disabilities Research Group. Department of Psychiatry. University of Cambridge. Douglas House) ; Annus, Tiina (Cambridge Intellectual and Developmental Disabilities Research Group. Department of Psychiatry. University of Cambridge. Douglas House) ; Osorio, R.S. (Healthy Brain Aging and Sleep Center. Department of Psychiatry. New York University. Grossman School of Medicine) ; Videla, S. (Institut d'Investigació Biomèdica de Bellvitge) ; Lehmann, S. (Le Laboratoire de Biochimie et Protéomique Clinique. Université Montpellier. Centre Hospitalier Universitaire Montpellier. Institut National de la Santé et de la Recherche Médicale) ; Holland, A.J. (Cambridge Intellectual and Developmental Disabilities Research Group. Department of Psychiatry. University of Cambridge. Douglas House) ; Zetterberg, H. (Department of Neurodegenerative Disease. UCL Queen Square Institute of Neurology) ; Blennow, K. (Clinical Neurochemistry Laboratory. Sahlgrenska University Hospital) ; Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Clarimón, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Zaman, S.H. (Cambridgeshire and Peterborough National Health Service (NHS) Foundation Trust. Fulbourn Hospital. Elizabeth House) ; Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Importance: Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Previous studies have suggested that the APOE ϵ4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce. [...]
2021 - 10.1001/jamaneurol.2021.1893
JAMA Neurology, Vol. 78 Núm. 8 (august 2021) , p. 937-947  
4.
12 p, 2.0 MB Sleep/wake cycle alterations as a cause of neurodegenerative diseases : A Mendelian randomization study / Cullell, Natalia (Universitat de Barcelona. Facultat de Medicina i Ciències de la Salut) ; Cárcel-Márquez, Jara (Institut d'Investigació Biomèdica Sant Pau) ; Gallego-Fabrega, Cristina (Institut d'Investigació Biomèdica Sant Pau) ; Muiño, Elena (Institut d'Investigació Biomèdica Sant Pau) ; Llucià-Carol, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Lledós, Miquel (Institut d'Investigació Biomèdica Sant Pau) ; Amaut, K.E.U. (AdSalutem Institute Sleep Medicine) ; Krupinski, J. (Department of Neurology. Hospital Universitari MútuaTerrassa / Fundació Docència i Recerca MútuaTerrassa. // Centre for bioscience. School of HealthCare Science. Manchester Metropolitan University. Manchester. UK) ; Fernandez-Cadenas, Israel (Institut d'Investigació Biomèdica Sant Pau)
Sleep and/or wake cycle alterations are common in neurodegenerative diseases (ND). Our aim was to determine whether there is a causal relationship between sleep and/or wake cycle patterns and ND (Parkinson's disease (PD) age at onset (AAO), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS)) using two-sample Mendelian Randomization (MR). [...]
2021 - 10.1016/j.neurobiolaging.2021.05.008
Neurobiology of Aging, Vol. 106 (october 2021) , p. 320.e1-320.e12  
5.
23 p, 7.9 MB Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease / Holstege, Henne (Delft Bioinformatics Lab, Delft University of Technology) ; Hulsman, Marc (Delft Bioinformatics Lab, Delft University of Technology) ; Charbonnier, Camille (Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ) ; Grenier-Boley, Benjamin (Université Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et déterminants moléculaires des maladies liées au vieillissement) ; Quenez, Olivier (Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ) ; Grozeva, Detelina (Cardiff University. Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine) ; van Rooij, Jeroen G. J. (Erasmus Medical Centre. Department of Internal Medicine) ; Sims, Rebecca (Cardiff University. Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine) ; Ahmad, Shahzad (Leiden Academic Centre for Drug Research) ; Amin, Najaf (Nuffield Department of Population Health Oxford University) ; Norsworthy, Penny J. (Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases) ; Dols Icardo, Oriol (Institut d'Investigació Biomèdica Sant Pau) ; Hummerich, Holger (Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases) ; Kawalia, Amit (Faculty of Medicine and University Hospital Cologne, University of Cologne. Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy) ; Amouyel, Philippe (Université Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et déterminants moléculaires des maladies liées au vieillissement) ; Beecham, Gary W. (The John P. Hussman Institute for Human Genomics, University of Miami) ; Berr, Claudine (Université Montpellier, INSERM, Institute for Neurosciences of Montpellier) ; Bis, Joshua C. (University of Washington. Cardiovascular Health Research Unit, Department of Medicine) ; Boland, Anne (Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Centre National de Recherche en Génomique Humaine Evry) ; Bossù, Paola (Istituto di Ricovero e Cura a Carattere Scientifico Santa Lucia Foundation. Experimental Neuro-psychobiology Laboratory, Department of Clinical and Behavioral Neurology) ; Bouwman, Femke (Amsterdam Neuroscience, Neurodegeneration) ; Bras, Jose (Michigan State University College of Human Medicine. Division of Psychiatry and Behavioral Medicine) ; Campion, Dominique (Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ) ; Cochran, J. Nicholas (HudsonAlpha Institute for Biotechnology) ; Daniele, Antonio (Catholic University of Sacred Heart, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico. Department of Neuroscience) ; Dartigues, Jean-François (Université Bordeaux, INSERM, Bordeaux Population Health Research Center) ; Debette, Stéphanie (Bordeaux University Hospital. Department of Neurology) ; Deleuze, Jean-François (Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Centre National de Recherche en Génomique Humaine Evry) ; Denning, Nicola (Cardiff University. UKDRI Cardiff, School of Medicine) ; DeStefano, Anita L. (Boston University School of Medicine. Department of Neurology) ; Farrer, Lindsay A. (Boston University. Department of Medicine (Biomedical Genetics)) ; Fernández, Maria Victoria (Washington University School of Medicine. Hope Center for Neurological Disorders) ; Fox, Nick C. (University College London Queen Square Institute of Neurology. Dementia Research Centre) ; Galimberti, Daniela (University of Milan) ; Genin, Emmanuelle (Université Brest, INSERM, Etablissement Français du Sang, Centre Hospitalier Universitaire Brest, Unité Mixte de Recherche 1078, GGB, Brest, France) ; Gille, Johan J. P. (VU University, AmsterdamUMC (location VUmc). Genome Diagnostics, Department of Human Genetics) ; Le Guen, Yann (Stanford University. Department of Neurology and Neurological Sciences) ; Guerreiro, Rita (Michigan State University College of Human Medicine. Division of Psychiatry and Behavioral Medicine) ; Haines, Jonathan L. (Case Western Reserve University. Department of Epidemiology and Biostatistics) ; Holmes, Clive (University of Southampton. Clinical and Experimental Science, Faculty of Medicine) ; Ikram, M. Arfan (Erasmus Medical Centre. Department of Epidemiology) ; Ikram, M. Kamran (Erasmus Medical Centre. Department of Epidemiology) ; Jansen, Iris E. (Vrije University. Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience) ; Kraaij, Robert (Erasmus Medical Centre. Department of Internal Medicine) ; Lathrop, Marc (McGill University and Genome Quebec Innovation Centre) ; Lemstra, Afina W. (Amsterdam Neuroscience, Neurodegeneration) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Luckcuck, Lauren (Cardiff University. Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine) ; Mannens, Marcel M. A. M. (University of Amsterdam, Amsterdam Reproduction and Development Research Institute. Department of Human Genetics, Amsterdam UMC) ; Marshall, Rachel (Cardiff University. Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine) ; Martin, Eden R. (University of Miami. Dr. John T. Macdonald Foundation Department of Human Genetics) ; Masullo, Carlo (Institute of Neurology, Catholic University of the Sacred Heart) ; Mayeux, Richard (Columbia University. Gertrude H. Sergievsky Center) ; Mecocci, Patrizia (University of Perugia. Institute of Gerontology and Geriatrics, Department of Medicine and Surgery) ; Meggy, Alun (Cardiff University. UKDRI Cardiff, School of Medicine) ; Mol, Merel O. (Erasmus Medical Centre. Department of Neurology) ; Morgan, Kevin (University of Nottingham. Human Genetics, School of Life Sciences) ; Myers, Richard M. (HudsonAlpha Institute for Biotechnology) ; Nacmias, Benedetta (IRCCS Fondazione Don Carlo Gnocchi) ; Naj, Adam C. (University of Pennsylvania Perelman School of Medicine. Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine) ; Napolioni, Valerio (Genomic and Molecular Epidemiology Laboratory, School of Biosciences and Veterinary Medicine, University of Camerino) ; Pasquier, Florence (Université Lille, INSERM, Centre Hospitalier Universitaire Lille, UMR1172, Resources and Research Memory Center (MRRC) of Distalz, Licend) ; Pastor, Pau (Hospital Universitari Mutua de Terrassa. Memory Disorders Unit, Department of Neurology) ; Pericak-Vance, Margaret A. (University of Miami. Dr. John T. Macdonald Foundation Department of Human Genetics) ; Raybould, Rachel (Cardiff University. UKDRI Cardiff, School of Medicine) ; Redon, Richard (Université de Nantes, Centre Hospitalier Universitaire Nantes, Centre National de la Recherche Scientifique, INSERM, l'institut du Thorax) ; Reinders, Marcel J. T. (Delft Bioinformatics Lab, Delft University of Technology) ; Richard, Anne-Claire (Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ) ; Riedel-Heller, Steffi G. (Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig) ; Rivadeneira, Fernando (Erasmus Medical Centre. Department of Internal Medicine) ; Rousseau, Stéphane (Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ) ; Ryan, Natalie S. (University College London Queen Square Institute of Neurology. Dementia Research Centre) ; Saad, Salha (Cardiff University. Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine) ; Sánchez-Juan, Pascual (Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL)) ; Schellenberg, Gerard D. (University of Pennsylvania Perelman School of Medicine. Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine) ; Scheltens, Philip (Amsterdam Neuroscience, Neurodegeneration) ; Schott, Jonathan M. (University College London Queen Square Institute of Neurology. Dementia Research Centre) ; Seripa, Davide (Laboratory for Advanced Hematological Diagnostics, Department of Hematology and Stem Cell Transplant, Lecce, Italy) ; Seshadri, Sudha (Department of Psychiatry and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX USA) ; Sie, Daoud (VU University, AmsterdamUMC (location VUmc). Genome Diagnostics, Department of Human Genetics) ; Sistermans, Erik A. (VU University, AmsterdamUMC (location VUmc). Genome Diagnostics, Department of Human Genetics) ; Sorbi, Sandro (IRCCS Fondazione Don Carlo Gnocchi) ; van Spaendonk, Resie (VU University, AmsterdamUMC (location VUmc). Genome Diagnostics, Department of Human Genetics) ; Spalletta, Gianfranco (Istituto di Ricovero e Cura a Carattere Scientifico Santa Lucia Foundation. Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology) ; Tesi, Niccolo (Delft Bioinformatics Lab, Delft University of Technology) ; Tijms, Betty (Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc. Alzheimer Center Amsterdam, Neurology) ; Uitterlinden, André G. (Erasmus Medical Centre. Department of Internal Medicine) ; van der Lee, Sven J. (Delft Bioinformatics Lab, Delft University of Technology) ; Visser, Pieter Jelle (Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc. Alzheimer Center Amsterdam, Neurology) ; Wagner, Michael (German Center for Neurodegenerative Diseases) ; Wallon, David (Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Neurology and CNRMAJ) ; Wang, Li-San (University of Pennsylvania Perelman School of Medicine. Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine) ; Zarea, Aline (Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Neurology and CNRMAJ) ; Clarimón, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; van Swieten, John C. (Erasmus Medical Centre. Department of Neurology) ; Greicius, Michael D. (Stanford University. Department of Neurology and Neurological Sciences) ; Yokoyama, Jennifer S. (University of California. Memory and Aging Center, Department of Neurology) ; Cruchaga, Carlos (Washington University School of Medicine. Hope Center for Neurological Disorders) ; Hardy, John (University College London Institute of Neurology. Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience) ; Ramirez, Alfredo (University of Cologne. Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases) ; Mead, Simon (University College London. Institute of Prion Diseases) ; van der Flier, Wiesje M. (Amsterdam Neuroscience, Neurodegeneration) ; van Duijn, Cornelia M. (Nuffield Department of Population Health Oxford University) ; Williams, Julie (Cardiff University. Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,, Division of Psychological Medicine and Clinical Neuroscience, School of Medicine) ; Nicolas, Gaël (Université Rouen Normandie, INSERM U1245 and CHU Rouen, Department of Genetics and CNRMAJ) ; Bellenguez, Céline (Université Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et déterminants moléculaires des maladies liées au vieillissement) ; Lambert, Jean-Charles (Université Lille, INSERM, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et déterminants moléculaires des maladies liées au vieillissement) ; Universitat Autònoma de Barcelona
Alzheimer's disease (AD), the leading cause of dementia, has an estimated heritability of approximately 70% . The genetic component of AD has been mainly assessed using genome-wide association studies, which do not capture the risk contributed by rare variants . [...]
2022 - 10.1038/s41588-022-01208-7
Nature genetics, Vol. 54 (november 2022) , p. 1786-1794  
6.
12 p, 1.2 MB Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease : additional results from the AMBAR study / Cuberas-Borrós, Gemma (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Roca, Isabel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Castell-Conesa, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Núñez, Laura (Alzheimer's Research Group (Barcelona)) ; Boada, Mercè (Instituto de Salud Carlos III) ; López, Oscar L. (University of Pittsburgh School of Medicine) ; Grifols, Carlota (Alzheimer's Research Group (Barcelona)) ; Barceló Torns, Miquel (Alzheimer's Research Group (Barcelona)) ; Pareto, Deborah (Hospital Universitari Vall d'Hebron) ; Páez, Antonio (Alzheimer's Research Group (Barcelona)) ; Universitat Autònoma de Barcelona
This study was designed to detect structural and functional brain changes in Alzheimer's disease (AD) patients treated with therapeutic plasma exchange (PE) with albumin replacement, as part of the recent AMBAR phase 2b/3 clinical trial. [...]
2022 - 10.1007/s00259-022-05915-5
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49 (july 2022) , p. 4589-4600  
7.
15 p, 2.1 MB Sex-specific metabolic pathways were associated with alzheimer's disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort / Xu, J. (King's College London) ; Green, R. (King's College London) ; Kim, M. (Steno Diabetes Center) ; Lord, J. (King's College London) ; Ebshiana, A. (King's College London) ; Westwood, S. (Department of Psychiatry. University of Oxford) ; Baird, A. L. (Department of Psychiatry. University of Oxford) ; Nevado-Holgado, Alejo (Department of Psychiatry. University of Oxford) ; Shi, L. (Department of Psychiatry. University of Oxford) ; Hye, Abdul (King's College London) ; Snowden, S. G. (King's College London) ; Bos, I. (Amsterdam UMC. University Medical Center) ; Vos, S. J. B. (Maastricht University) ; Vandenberghe, R. (Alzheimer Center. VU University Medical Center) ; Teunissen, C. E. (Department of Radiology and Nuclear Medicine. VU University Medical Center) ; Kate, M. T. (Department of Radiology and Nuclear Medicine. VU University Medical Center) ; Scheltens, P. (Alzheimer Center. VU University Medical Center) ; Gabel, Silvy (University Hospitals Leuven (Bèlgica)) ; Meersmans, K. (University Hospitals Leuven (Bèlgica)) ; Blin, Olivier (Clinical Pharmacology & Pharmacovigilance Department. Aix-Marseille University-CNRS) ; Richardson, J. (Neurosciences Therapeutic Area. GlaxoSmithKline R&D) ; De Roeck, E. E. (Reference Center for Biological Markers of Dementia (BIODEM). Institute Born-Bunge. University of Antwerp) ; Engelborghs, S. (Reference Center for Biological Markers of Dementia (BIODEM). Institute Born-Bunge. University of Antwerp) ; Sleegers, K. (Complex Genetics of Alzheimer's Disease Group. VIB Center for Molecular Neurology. VIB) ; Bordet, Régis (Department of Medical Pharmacology. Université de Lille) ; Rami, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Kettunen, Petronella (Institute of Neuroscience and Physiology. Sahlgrenska Academy. University of Gothenburg) ; Tsolaki, M. (AHEPA University Hospital (Grècia)) ; Verhey, F. R. J. (Department of Psychiatry and Neuropsychology. School for Mental Health and Neuroscience. Alzheimer Centrum Limburg. Maastricht University) ; Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Peyratout, G. (Lausanne University Hospital) ; Tainta, Mikel (Fundación CITA-Alzhéimer Fundazioa) ; Johannsen, P. (Danish Dementia Research Centre. Rigshospitalet) ; Freund-Levi, Y. (King's College London) ; Frölich, L. (Department of Geriatric Psychiatry. Central Institute of Mental Health. Medical Faculty Mannheim. University of Heidelberg) ; Dobricic, Valerija (Lübeck Interdisciplinary Platform for Genome Analytics. Institutes of Neurogenetics and Cardiogenetics. University of Lübeck) ; Frisoni, G. B. (IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli) ; Molinuevo, J. L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Wallin, A. (Institute of Neuroscience and Physiology. Sahlgrenska Academy. University of Gothenburg) ; Popp, J. (Department of Geriatric Psychiatry. University Hospital of Psychiatry Zürich) ; Martinez-Lage, P. (Center for Research and Advanced Therapies. CITA-Alzheimer Foundation) ; Bertram, L. (Department of Psychology. University of Oslo) ; Blennow, K. (Department of Psychiatry and Neurochemistry. Institute of Neuroscience and Physiology. Sahlgrenska Academy. University of Gothenburg) ; Zetterberg, Henrik (Department of Neurodegenerative Disease. UCL Institute of Neurology) ; Streffer, J. (Reference Center for Biological Markers of Dementia (BIODEM). Institute Born-Bunge. University of Antwerp) ; Jelle Visser, P. (Department of Psychiatry and Neuropsychology. School for Mental Health and Neuroscience. Alzheimer Centrum Limburg. Maastricht University) ; Lovestone, Simon (Janssen-Cilag UK Ltd.) ; Proitsi, P. (King's College London) ; Legido-Quigley, C. (Steno Diabetes Center) ; Universitat Autònoma de Barcelona
Background: physiological differences between males and females could contribute to the development of Alzheimer's Disease (AD). Here, we examined metabolic pathways that may lead to precision medicine initiatives. [...]
2021 - 10.3390/biomedicines9111610
Biomedicines, Vol. 9 Núm. 11 (november 2021) , p. 1610  
8.
10 p, 3.4 MB Alternative platelet activation pathways and their role in neurodegenerative diseases / Ferrer Raventós, Paula (Institut d'Investigació Biomèdica Sant Pau) ; Beyer, Katrin (Institut Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Purpose of the review: The study of platelets in the context of neurodegenerative diseases is intensifying, and increasing evidence suggests that platelets may play an important role in the pathogenesis of neurodegenerative disorders. [...]
2021 - 10.1016/j.nbd.2021.105512
Neurobiology of Disease, Vol. 159 (november 2021) , p. 105512  
9.
11 p, 2.8 MB Revealing cell vulnerability in Alzheimer's disease by single-cell transcriptomics / Saura, Carlos A. (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Deprada, Angel (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Capilla-López, Maria Dolores (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Parra-Damas, Arnaldo (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Alzheimer's disease (AD) is a neurodegenerative disorder that by affecting specific brain cell types and regions cause severe pathological and functional changes in memory neural circuits. A comprehensive knowledge of the pathogenic mechanisms underlying AD requires a deeper understanding of the cell-specific pathological responses through integrative molecular analyses. [...]
2022 - 10.1016/j.semcdb.2022.05.007
Seminars in Cell and Developmental Biology, 2022  
10.
16 p, 2.1 MB Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease / Visser, Pieter Jelle (Karolinska Institutet (Estocolm, Suècia)) ; Reus, Lianne M. (Vrije Universiteit Amsterdam) ; Gobom, Johan (Sahlgrenska Academy at the University of Gothenburg) ; Jansen, Iris (VU University) ; Dicks, Ellen (Vrije Universiteit Amsterdam) ; van der Lee, Sven J. (Vrije Universiteit Amsterdam) ; Tsolaki, Magda (AHEPA University Hospital (Grècia)) ; Verhey, Frans R. J. (Maastricht University) ; Popp, Julius (University Hospital Zurich (Suïssa)) ; Martinez-Lage, Pablo (Fundación CITA-Alzhéimer Fundazioa) ; Vandenberghe, Rik (KU Leuven) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Molinuevo, José Luís (Hospital Clínic i Provincial de Barcelona) ; Engelborghs, Sebastiaan (Vrije Universiteit Brussel) ; Freund-Levi, Yvonne (Örebro University) ; Froelich, Lutz (University of Heidelberg) ; Sleegers, Kristel (University of Antwerp) ; Dobricic, Valerija (University of Lübeck) ; Lovestone, Simon (High Wycombe, UK) ; Streffer, Johannes (AC Immune SA) ; Vos, Stephanie J. B. (Maastricht University) ; Bos, Isabelle (Maastricht University) ; Smit, August B. (Vrije Universiteit Amsterdam) ; Blennow, Kaj (Sahlgrenska Academy at the University of Gothenburg) ; Scheltens, Philip (Vrije Universiteit Amsterdam) ; Teunissen, Charlotte E. (Amsterdam University Medical Centers (AUMC)) ; Bertram, Lars (University of Oslo) ; Zetterberg, Henrik (Dementia Research Institute at UCL) ; Tijms, Betty M. (Vrije Universiteit Amsterdam) ; Universitat Autònoma de Barcelona
Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can be increased in very early disease stages, when neurodegeneration is limited, and can be normal in advanced disease stages. [...]
2022 - 10.1186/s13024-022-00521-3
Molecular neurodegeneration, Vol. 17 (march 2022)  

Articles : 117 registres trobats   1 - 10següentfinal  anar al registre:
Documents de recerca 108 registres trobats  1 - 10següentfinal  anar al registre:
1.
161 p, 22.2 MB Complex Neuroimaging Changes in Metabolite, Cortical Structures and Regional Vulnerabilities in the Alzheimer Disease Continuum / Montal Blancafort, Victor ; Fortea, Juan, dir. ; Lleo, Alberto, dir.
La enfermedad de Alzheimer es la principal causa de demencia. Patológicamente, está caracterizada por tau hiperfosforilada intracelular y el depósito de placas de amiloide extracelular. Estos procesos fisiopatológicos empiezan décadas antes de que aparezca el deterioro cognitivo, y conllevan atrofia cerebral y neurodegeneracion. [...]
Alzheimer disease (AD) is the most important cause of dementia. Its histopathological hallmarks are intracellular hyperphosphorylated tau and extracellular amyloid plaques, which start to accumulate decades before the onset of clinical symptoms and eventually lead to neurodegeneration and brain atrophy. [...]

2022  
2.
93 p, 5.1 MB Mixed neurodegenerative dementia : the coexistence of dementia with Lewy bodies and Alzheimer's disease : / Abdelnour, Carla ; Pagonabarraga Mora, Javier, dir. ; Aarsland, Dag, dir. ; Kulisevsky, Jaime, dir.
La demència amb cossos de Lewy (DCL) és la segona causa més freqüent de demència neurodegenerativa, i un alt percentatge de casos mostra copatologia amb la malaltia d'Alzheimer (EA). Els pacients amb DCL i EA concomitant tenen un major risc d'ingrés en residència, menor tassa de supervivència i progressió més ràpida a la demència. [...]
La demencia con cuerpos de Lewy (DCL) es la segunda causa más frecuente de demencia neurodegenerativa, y un alto porcentaje de casos muestra copatología con la enfermedad de Alzheimer (EA). Los pacientes con DCL y EA concomitante tienen un mayor riesgo de ingreso en residencia, menor tasa de supervivencia y progresión más rápida a la demencia. [...]
Dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative dementia, and a high percentage of cases show Alzheimer's disease (AD) copathology. Patients with DLB and concomitant AD have increased risk of nursing home admission, shorter survival rates, and faster progression to dementia. [...]

2022  
3.
2 p, 788.3 KB One step closer towards Alzheimer's cure / Perlaza Meneses, Danna Alejandra ; Universitat Autònoma de Barcelona. Facultat de Biociències
2022
Grau en Genètica [833]  
4.
212 p, 5.4 MB Búsqueda de nuevos biomarcadores en la Angiopatía Amiloide Cerebral / Marazuela Fuentes, Paula ; Hernández Guillamon, Mar, dir. ; Montaner Villalonga, Juan Bernardo, dir.
La β-amiloidosis cerebral es caracteritza per l'acumulació anòmala del pèptid beta amiloide (Aß) en el parènquima i en la paret dels vasos cerebrals, constituint una de les principals característiques neuropatològiques de la Malaltia d'Alzheimer (MA) i de l'angiopatia amiloide cerebral (AAC). [...]
La β-amiloidosis cerebral se caracteriza por la acumulación anómala del péptido beta amiloide (Aβ) en el parénquima y en la pared de los vasos cerebrales, constituyendo una de las principales características neuropatológicas de la Enfermedad de Alzheimer (EA) y de la Angiopatía Amiloide Cerebral (AAC), respectivamente. [...]
Cerebral β-amyloidosis is characterized by parenchymal and vascular deposition of amyloid beta-peptide (Aβ), which are major features of Alzheimer's disease (AD) and Cerebral Amyloid Angiopathy (CAA), respectively. [...]

2021  
5.
200 p, 9.0 MB Estudio patológico de biomarcadores en la Angiopatía Amiloide Cerebral y la Enfermedad de Alzheimer / Camacho Soriano, Jessica ; Martínez Sáez, Elena Antima, dir. ; Hernández Guillamon, Mar, dir. ; Ramón y Cajal Agüeras, Santiago, dir.
Introducció: Nombrosos estudis suggereixen que el deteriorament cognitiu en el cervell ancià típicament presenta un solapament entre patologies neurodegeneratives i vasculars. La malaltia neurodegenerativa més freqüent seria la malaltia d'Alzheimer (MA) i entre les etiologies vasculars més freqüents es troba l'angiopatia amiloide cerebral (AAC). [...]
Introducción: Numerosos estudios sugieren que el deterioro cognitivo en el cerebro anciano típicamente presenta un solapamiento entre patologías neurodegenerativas y vasculares. La enfermedad neurodegenerativa más frecuente sería la enfermedad de Alzheimer (EA) y entre las etiologías vasculares más frecuentes se encuentra la angiopatía amiloide cerebral (AAC). [...]
Introduction: Numerous studies suggest that cognitive impairment in the elderly brain typically presents an overlap between neurodegenerative and vascular pathologies. The most common neurodegenerative disease would be Alzheimer's disease (AD) and among the most common vascular etiologies would be cerebral amyloid angiopathy (CAA). [...]

2021  
6.
25 p, 2.7 MB Dany Cerebral Traumàtic : factor de risc en l'aparició de malalties neurodegeneratives? / Negredo i Ballesté, Pol ; Costa Miserachs, David, dir. ; Universitat Autònoma de Barcelona. Facultat de Psicologia
Aquest treball de revisió ha intentat donar resposta a la incògnita de si els danys cerebrals traumàtics (Traumatic Brian Injury en anglès = TBI) suposen o no un factor de risc per a la futura aparició de les malalties neurodegeneratives d'Alzheimer i Parkinson. [...]
This review will try to answer the question about whether or not Traumatic brain injury is supposed to be a risk factor for the onset of Alzheimer and Parkinson's. To do so, a review of scientific literature has been made to obtain information about either epidemiological data related to these two conditions and regarding the biological mechanisms triggered by the TBI, which may be the underlying cause of that future neurodegeneration. [...]

2021
Grau en Psicologia [1485]  
7.
2 p, 743.9 KB The ac-K174 Tau as a biomarker for the early-diagnosis of Alzheimer Disease and a device for its detection / Hernández, C. ; Universitat Autònoma de Barcelona. Facultat de Biociències
The Alzheimer's Disease (AD) is the most common form of dementia, characterized by memory loss, cognitive decline and neurodegeneration. It is caused principally by the accumulation of amyloid beta (Aß) peptide and Tau protein. [...]
2021
Grau en Biotecnologia [815]  
8.
464 p, 32.5 MB Por si no recuerdas : ideación, diseño y preproducción de una serie melodramática sobre el Alzheimer para una plataforma VoD / Margalef Alsina, Maria ; Ruano Castro, Beatriz ; Gomez, Angel Custodio, dir. (Universitat Autònoma de Barcelona. Departament de Comunicació Audiovisual i Publicitat) ; Universitat Autònoma de Barcelona. Facultat de Ciències de la Comunicació
Projecte d'ideació d'un melodrama familiar en format sèrie pensat per a ser produït posteriorment per a una plataforma. Por si no recuerdas, que té com a temàtica principal l'Alzheimer, retrata l'impacte que suposa aquesta malaltia no sols per a qui la pateix, sinó també per al seu entorn. [...]
Proyecto de ideación de un melodrama familiar en formato serie pensado para ser producido posteriormente para una plataforma. Por si no recuerdas, que tiene como temática principal el Alzheimer, retrata el impacto que supone esta enfermedad no solo para quien la sufre, sino también para su entorno. [...]
Ideation project of a family melodrama in serial format intended to be produced later for a platform. Por si no recuerdas, which has Alzheimer's as its main theme, shows the impact of this disease not only for those who suffer from it, but also for their family. [...]

2021
Grau en Comunicació Audiovisual [968]  
9.
237 p, 5.8 MB Associació entre la bateria cognitiva neuronorma i els biomarcadors de líquid cefaloraquidi en el contínuum de la malaltia d'Alzheimer / García-Escobar, Greta ; Peña-Casanova, J. (Jordi), dir. ; Sánchez Benavides, Gonzalo, dir.
La malaltia d'Alzheimer (MA) es caracteritza per un deteriorament cognitiu de tipus progressiu. Les valoracions neuropsicològiques són fonamentals per a definir el perfil d'afectació i contribuir al diagnòstic. [...]
La enfermedad de Alzheimer (EA) se caracteriza por un deterioro cognitivo de tipo progresivo. Las valoraciones neuropsicológicas son fundamentales para definir el perfil de afectación y contribuir al diagnóstico. [...]
Alzheimer's disease (AD) is characterized by progressive cognitive impairment. Neuropsychological assessments are essential to define the profile of those cognitive changes and to contribute to their diagnosis. [...]

2020  
10.
244 p, 6.7 MB Role of Nr4a2 transcription factor in hippocampal synaptic plasticity. Possible therapeutic target for Alzheimer's disease / Català-Solsona, Judit ; Rodríguez Álvarez, José, dir.
Actualment no existeixen estratègies efectives per prevenir o curar la patologia d'Alzheimer. Per combatre una malaltia amb una fase prodròmica tant llarga, és crucial entendre els mecanismes alterats en estadis inicials. [...]
Actualmente no existen estrategias eficaces para prevenir o tratar la enfermedad de Alzheimer. Para combatir una enfermedad con una fase prodrómica tan larga, es crucial entender los mecanismos alterados en etapas tempranas. [...]
Effective strategies to prevent or treat Alzheimer's pathology remain elusive. To confront a disease with such a long prodromal phase is crucial to understand the mechanisms altered at early stages. [...]

2020  

Documents de recerca : 108 registres trobats   1 - 10següentfinal  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.